The out-sourced drug development company, RxCelerate Ltd, announced today that it has completed the acquisition of Cambridge-based specialist bioanalytical contract research organisation, Total Scientific Ltd.
RxCelerate, which has offices in Cambridge, MA and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible.
Total Scientific was founded in 2006, on the Babraham Research Campus, and specialises in measuring complex drugs and proteins in biological samples, compliant with Good Laboratory Practice (GLP).
“Total Scientific was the first company in the world to offer Phenome-wide Association Studies (PheWAS) as a commercial service, underpinning their status as global leaders in highly specialised bioanalysis” said Dr Jill Reckless, CEO of RxCelerate. “This capability, coupled with their GLP-compliant bioanalysis platform significantly extends the range of cutting-edge capabilities available to our clients to move their projects more efficiently to the next value inflection point.”
Dr David Mosedale, Founder and Chief Scientist at Total Scientific, said “We built a fantastic team at Total Scientific over the last ten years, who have solved many challenging problems for our clients. But the opportunity to become part of the RxCelerate group with their global reach into US markets, allowing even more drug developers to benefit from services like PheWAS, which we have pioneered, was simply too good to pass up.”